FREE SHIPFree U.S. shipping on orders over $150Free U.S. shipping on orders over $150
Free U.S. shipping on orders over $150
Sermorelin is a synthetic analog of growth hormone–releasing hormone (GHRH). GHRH is a naturally occurring peptide secreted by the hypothalamus to stimulate growth hormone (GH) production in the anterior pituitary gland.
Structurally, sermorelin is a 29–amino acid peptide fragment of GHRH that retains full biological activity in terms of binding to pituitary receptors and triggering GH release [1].
Originally, sermorelin was developed as a diagnostic tool to assess pituitary function. Over time, its use has expanded into research exploring potential roles as a secretagogue in endocrine regulation, metabolism, and aging biology.
Sermorelin stimulates the pituitary to produce and secrete GH, which in turn drives the liver and peripheral tissues to generate insulin-like growth factor-1 (IGF-1), the primary mediator of bone elongation and linear growth.
Clinical trials in children with impaired growth velocity have shown that sermorelin administration can increase growth rate and promote catch-up growth.
Specifically, once-daily subcutaneous Sermorelin (30 µg/kg body weight) at bedtime was effective in treatment of prepubertal children with idiopathic GH deficiency [2].
Although sermorelin-treated children demonstrated less height improvements compared to 30 µg/kg/day of somatropin (bioidentical GH), sermorelin was likely safer and better tolerated.
Unlike direct GH therapy, sermorelin does not appear to excessively elevate circulating GH or IGF-1 levels, potentially lowering the risk of disproportionate bone growth or metabolic complications.
In this context, sermorelin is best understood as a diagnostic and therapeutic tool that can support normal developmental trajectories in children with specific types of growth impairment.
However, long-term data remain limited, and not all forms of growth delay respond equally, underscoring the importance of careful patient selection in research and clinical settings.
Preclinical studies suggest that GHRH analogs similar to sermorelin can exert anti-proliferative effects in certain cancer models. Mechanistically, these peptides appear to influence signaling pathways that regulate apoptosis, angiogenesis, and cell cycle progression [3].
A transcriptomic screen for candidate compounds in treatment-resistant glioma patients identified sermorelin as a candidate compound effective against the glioma [4].
Among screened compounds, sermorelin emerged as the most promising agent for recurrent gliomas, especially those with high-grade tumors, IDH-wildtype status, and 1p/19q non-codeletion.
This study suggests that sermorelin may inhibit glioma cell proliferation by blocking the cell cycle, although clinical validation is required.
GH and IGF-1 support osteoblast activity, increase bone turnover, and may help reverse age‐related loss of bone mass. These hormones also support muscle growth and maintenance along with tissue repair [5, 6]. As a GH secretagogue, sermorelin may mitigate some aspects of age-related decline in bone health. However, specific trials of sermorelin in aging adults focused on bone density remain limited.
A single-blind, randomized, placebo-controlled trial of 19 people investigated the effects of nightly subcutaneous sermorelin at 10 µg/kg for 16 weeks. Results showed [7]:
While body weight, fat mass, and testosterone levels remained stable, these findings suggest sermorelin may mitigate age-related GH/IGF-1 decline and corresponding muscle mass loss.
In clinical and research use, sermorelin has generally been regarded as safe and well tolerated, especially in comparison to direct recombinant growth hormone therapy.
Because it acts as a secretagogue, stimulating the body’s own pulsatile growth hormone release rather than providing supraphysiologic doses, its endocrine profile is considered closer to natural physiology.
The most frequently reported adverse effects are mild and transient, such as injection site reactions, flushing sensation, and nausea.
Serious side effects are rare in published reports, and no consistent evidence suggests long-term harm at research dosages.
However, as with other growth hormone-modulating therapies, caution is advised in individuals with active malignancy, since GH and IGF-1 pathways can influence cell proliferation.
Overall, the safety data indicate a favorable risk profile for sermorelin within short- to medium-term use, though robust long-term clinical studies are limited.
Every lot undergoes five independent assays before release. Results are published in the lot-specific Certificate of Analysis.
Every lot undergoes our 4-panel testing protocol: HPLC purity analysis, ESI-MS identity confirmation, LAL endotoxin screening, and amino acid analysis (for peptides >15 residues). Full analytical data is published in the Certificate of Analysis for each lot.
Lyophilized peptides should be stored at -20°C or below for long-term stability. Once reconstituted, peptides should be stored at 2–8°C and used within a reasonable timeframe depending on the specific compound. Avoid repeated freeze-thaw cycles. Always store in a dry environment away from direct light.
Orders placed before noon PST, Monday–Saturday, ship the same day. We offer free standard shipping on orders over $150. All orders are shipped in insulated packaging with ice packs when necessary. Standard delivery typically takes 2–4 business days within the continental US.
No. All compounds sold by Genesis Peptides are strictly for in vitro and preclinical laboratory research purposes only. They are not approved for human consumption, therapeutic use, or diagnostic purposes. By purchasing, you confirm the products will be used solely for legitimate research applications.
A Certificate of Analysis (COA) is a document issued by our analytical laboratory that reports the results of all quality control tests performed on a specific lot of product. Each COA includes HPLC chromatograms, mass spectra, endotoxin results, and amino acid analysis where applicable. COAs are available in our COA Library for every lot we have shipped.
Yes. We offer volume pricing for universities, research institutions, and laboratories with recurring needs. Discounts begin at 10+ units and scale with volume. Contact our team for a custom quote tailored to your research requirements.
— Products are sold exclusively for in vitro and preclinical laboratory research. Not for human consumption or administration. Not intended for diagnostic or therapeutic use. These statements have not been evaluated by the FDA.
Research Use Only. All findings described above are derived from preclinical studies (animal models and in vitro experiments). Sermorelin is not approved by the FDA for any diagnostic or therapeutic use in humans. Genesis Peptides makes no claims regarding human clinical efficacy. This product is sold exclusively for laboratory research.
